[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100070577":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":11,"locations":11,"responsibleParty":28,"collaborators":11,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":11,"eligibilityCriteria":37,"healthyVolunteers":33,"sex":38,"minAge":39,"maxAge":40,"enrollmentInfo":41,"targetDuration":11,"studyType":44,"phases":45,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cyclosporine microemulsion","EXPERIMENTAL",null,[13],"Drug: Cyclosporine microemulsion",{"label":15,"type":16,"description":11,"interventionNames":17},"Tacrolimus","ACTIVE_COMPARATOR",[18],"Drug: Tacrolimus",[20,23],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":11},"DRUG",[9],{"type":21,"name":15,"description":11,"armGroupLabels":24,"otherNames":11},[15],[26],{"name":5,"affiliation":5,"role":27},"STUDY_DIRECTOR",{"type":11,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":29,"oldOrganization":30},"External Affairs","Novartis Pharmaceuticals","100070577","phase-4-evaluation-of-cyclosporine-microemulsion-and-tacrolimus-on-the-rate-of-new-onset-diabetes-mellitus-in-kidney-transplantation-recipients-100070577",false,"NCT00171496","Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients","A Six-month Open Label, Multicenter, Randomized Study to Evaluate the Incidence of New Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion With C-2 Monitoring Versus Tacrolimus After de Novo Kidney Transplantation","Inclusion Criteria:\n\n\\- First or second transplant, cadaveric or living donor\n\nExclusion Criteria:\n\n* Multi-organ or dual kidney transplants\n* Panel reactive antibodies \\>50%\n\nOther protocol-defined inclusion\u002Fexclusion criteria applied","ALL","18 Years","70 Years",{"count":42,"type":43},693,"ACTUAL","INTERVENTIONAL",[46],"PHASE4","The purpose of this study is to evaluate the impact of tacrolimus and cyclosporine microemulsion on glucose metabolism in kidney transplant recipients and the efficacy and safety in preventing organ rejection",[49],"Kidney Transplant",[51],"Kidney transplant, adults, NODM, immunosuppressants","COMPLETED","2016-11-16",{"date":55,"type":56},"2016-11-18","ESTIMATED",{"date":58,"type":11},"2003-10",{"date":60,"type":43},"2006-03",{"name":5,"class":6}]